Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission  by Brown, Jennifer R. et al.
L
M
F
I
t
t
t
b
s
s
s
n
s
Biology of Blood and Marrow Transplantation 13:1057-1065 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1309-0001$32.00/0
doi:10.1016/j.bbmt.2007.05.012ong-Term Survival after Autologous Bone
arrow Transplantation for Follicular Lymphoma in
irst Remission
Jennifer R. Brown,1,2,3 Yang Feng,4 John G. Gribben,1,2,3 Donna Neuberg,4 David C. Fisher,1,2,3
Peter Mauch,5,6 Lee M. Nadler,1,2,3 Arnold S. Freedman1,2,3
1Department of Medical Oncology, 4Department of Biostatistics and Computational Biology, Dana-Farber Cancer
Institute; 2Department of Medicine, 5Department of Radiation Oncology, Brigham and Women’s Hospital, Boston,
Massachusetts; 3Department of Medicine, 6Department of Radiation Oncology, Harvard Medical School, Boston,
Massachusetts
Correspondence and reprint requests: Arnold S. Freedman, MD, Department of Medical Oncology, Dana-Farber
Cancer Institute, 44 Binney Street, Boston, MA 02115 (e-mail: arnold_freedman@dfci.harvard.edu).
Received March 19, 2007; accepted May 22, 2007
ABSTRACT
The role of autologous stem cell transplantation (ASCT) in the treatment of follicular lymphoma is still being
defined in the era of antibody therapy. Here we report the long-term 12-year clinical outcomes of patients
treated with autologous bone marrow transplantation (ABMT) for follicular non-Hodgkin’s lymphoma (NHL)
in first remission. Between 1988 and 1993, advanced-stage follicular NHL patients in need of initial therapy
were enrolled in 2 consecutive prospective treatment trials of either standard-dose CHOP induction (83
patients) or high-dose CHOP plus granulocyte-colony stimulating factor (G-CSF) (20 patients). Patients who
achieved an adequate remission with induction therapy underwent conditioning with cyclophosphamide and
total body irradiation (TBI) followed by ABMT in first remission using bone marrow (BM) purged in vitro with
anti-B cell monoclonal antibodies and rabbit complement (96 patients). At 12-year follow-up, 61% of the
patients are alive and 43% remain in continuing complete remission. The only predictors of decreased
progression-free survival proved to be histologic BM involvement at time of harvest (hazard ratio [HR] 2.27,
95% confidence interval [CI] 1.3-3.9, P < .004) and PCR detectable disease in the BM product after purging
(HR 4.18, 95% CI 1.99-8.8, P  .0002). No significant predictors of overall survival were identified. These
results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged
survival with ABMT in first remission.
© 2007 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
The role of high-dose chemoradiotherapy and au-
ologous stem-cell transplantation (ASCT) in the
reatment of follicular lymphoma (FL) remains con-
roversial, particularly with the advent of antibody-
ased therapies. Multiple phase II studies in FL have
uggested that ASCT can result in prolonged remis-
ions, albeit at the cost of signiﬁcant toxicity, primarily
econdary myelodysplastic syndromes/acute myeloge-
ous leukemia (MDS/AML) and now increasingly
olid tumors [1-14]. (Since the initiation of these Phase II studies, mul-
iple randomized trials have now been reported that
ddress the role of ASCT in follicular non-Hodgkin’s
ymphoma (NHL). For relapsed patients, the Euro-
ean CUP trial found that 2-year progression-free
urvival (PFS) was improved from 26% with standard
hemotherapy to 55%-58% in the combined purged
nd unpurged ASCT arms, and that 4-year overall
urvival (OS) improved from 46% to 71%-77% [15].
or patients transplanted in ﬁrst remission, both the
erman Low-Grade Lymphoma Study GroupGLSG) and the GOELAMS group have reported
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J. R. Brown et al.1058igniﬁcantly improved PFS with ASCT, albeit in the
LSG case offset by increased second malignancies
11,16]. The GELA failed to see any PFS beneﬁt in an
ntent-to-treat analysis that included patients who did
ot respond to induction, and therefore did not re-
eive ASCT, and with a comparison arm that received
8 months of continuous therapy [17]. These studies
ave therefore suggested a beneﬁt of ASCT for relapsed
atients with FL, and have been inconclusive with re-
pect to patients in ﬁrst remission, raising the possibility
hat PFS may be improved, if secondary toxicities could
e minimized. In this study we report the very long-term
linical outcomes of a population of FL patients treated
ith autologous bone marrow transplantation (ABMT)
or consolidation of ﬁrst remission, with 43% of the
atients remaining in continuous complete remission
CCR) with few late relapses at a median follow-up of 12
ears.
ATIENTS AND METHODS
election of Patients and Treatment Protocol
Patient eligibility and selection were identical for
ach of these 2 sequential prospective studies. Patients
ere eligible for high-dose therapy and ABMT in ﬁrst
emission following CHOP induction if they met the
ollowing criteria: physiologic age 55 years or less;
reviously untreated follicular low-grade B cell NHL
s deﬁned by the Working Formulation (WF), includ-
ng: follicular small cleaved cell (WF-B), and follicular
ixed small cleaved and large cell (WF-C); and CD20
B1) antigen expression on their lymphoma cells as
reviously described [18]. All pathology was reviewed
t Brigham and Women’s Hospital. Patients had to
ave advanced stage disease, including IIIB, IIIE, II
ith masses10 cm, or stage IV disease. Patients with
tage IV disease with minimal adenopathy (1 cm)
nd 5% bone marrow (BM) involvement were ex-
luded. Additional criteria for entry included the ab-
ence of comorbid disease of the heart, kidney, lung,
nd liver, and a Karnofsky score 80%. All protocols
ere approved by the Dana-Farber Cancer Institute
DFCI) institutional review board, and informed con-
ent was obtained from all patients prior to therapy.
All patients were registered prior to initiation of
HOP; a subset of patients received their CHOP
nduction with their referring physicians. Eighty-
hree patients were treated with 6-8 cycles of SD-
HOP (cyclophosphamide 750 mg/m2 i.v. on day 1;
oxorubicin 50 mg/m2 i.v. on day 1; vincristine 1.4
g/m2 (maximum 2 mg) i.v. on day 1; and prednisone
00 mg/day orally on days 1-5). Twenty patients re-
eived 4 cycles of HD-CHOP every 3 weeks [19].
his regimen consisted of cyclophosphamide 1.5
/m2/day i.v. on days 1 and 2; doxorubicin 50 mg/m2 i.v.
n day 1; vincristine 1.4 mg/m2 (maximum 2 mg) i.v. on lay 1; and prednisone 100 mg/day orally on days 1-5.
esna was given by i.v. bolus as uroprotectant. Granu-
ocyte-colony stimulating factor (G-CSF) 5 g/kg/day
.c. was given on days 4-18 of each cycle. No dose
odiﬁcations were permitted on either protocol. All
atients received prophylactic acyclovir and tri-
ethoprim-sulfamethoxazole during each cycle.
At the completion of SD-CHOP or HD-CHOP,
atients in CR (1 cm lymph nodes and no BM
nvolvement) or minimal disease state (2 cm lymph
odes and 20% BM involvement, deﬁned as the
ercent involvement of the intertrabecular space on
liac crest biopsy) went on to BM harvest within 4
eeks of completing chemotherapy. After SD-CHOP,
0 patients (13%) with 1-3 masses 2 cm received in-
olved ﬁeld radiotherapy. After completion of HD-
HOP, 2 patients (11%) with 1 mass 2 cm received
nvolved ﬁeld radiotherapy.
In patients not receiving involved ﬁeld radiother-
py, admission for ABMT was within 4 weeks of BM
arvest. Conditioning therapy for ABMT consisted of
yclophosphamide 60 mg/kg infused on each of 2
onsecutive days before radiotherapy. Total body ir-
adiation (TBI) was administered in fractionated doses
200 cGy) twice daily on 3 consecutive days (total of
200 cGy) in all patients. Patients who were treated
ith SD-CHOP induction did not receive any hema-
opoietic growth factors following ABMT. All patients
ho received HD-CHOP induction received hema-
opoietic growth factors following ABMT. A signiﬁ-
ant prolongation of neutrophil and platelet en-
raftment was observed in patients who had received
D-CHOP with G-CSF, as previously reported
20]. Supportive care was provided as previously
escribed [21].
ollection, Processing, and Infusion of Marrow
BM was obtained, treated in vitro with anti-B1
CD20), -B5, and -J5 (anti-CD10) monoclonal anti-
odies (mAb) and rabbit complement, and cryopre-
erved as previously described [21]. Nested PCR am-
liﬁcation at the major breakpoint region (MBR) and
inor cluster region (mcr) of the bcl-2/IgH rear-
angement of t(14;18) were performed as previously
escribed; only those samples in which a rearrange-
ent could be detected in initial diagnostic material
ere considered evaluable [22]. No patients were ex-
luded from the protocol after BM harvest. Within
8 h of the completion of TBI the cryopreserved
arrow cells were reinfused as previously described
21]. No subjects treated on these protocols received
eripheral blood stem cells (PBSC).
ollow-up
All patients had routine physical examinations and
aboratory studies, including complete blood counts,
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Long-Term Results of ABMT for Follicular NHL in First Remission 1059very 3 months for the ﬁrst year, then every 6 months
or the second year, then annually following transplan-
ation. Patients underwent BM aspiration and core bi-
psy for persistently low peripheral blood counts with-
ut an obvious explanation. For those patients alive but
ot continuing to obtain follow-up care at DFCI, fol-
ow-up phone calls to their physicians were made annu-
lly.
lassification of MDS
As in our previous reports of MDS in this patient
opulation [4], MDS was strictly deﬁned using the
rench-American-British (FAB) classiﬁcation system
nd required BM dysplasia in at least 2 lineages with
eripheral cytopenia(s). Although cytogenetic abnor-
alities were evaluated, their presence was not diag-
ostic. Patients with persistent cytopenias after bone
arrow transplantation (BMT) without signiﬁcant
arrow dysplasia, or with alternative explanations for
heir cytopenias, were not considered to have MDS.
tatistical Methods
OS is deﬁned as the time from the day of marrow
nfusion (day 0) to death from any cause. PFS is
eﬁned as the time from the day of marrow infusion to
he ﬁrst reported outcome event. Outcome events
nclude progression of disease or death from any
ause. PFS and OS curves were obtained using the
aplan-Meier method, with 95% conﬁdence intervals
CI) calculated using Greenwood’s formula, and com-
ared by the log rank test [23,24]. The effects of the
otential prognostic factors for PFS and OS were
ssessed using Cox multivariable regression models.
The cumulative incidence of second malignancies
r relapse in the presence of competing risks (death
ithout second malignancies or death in remission,
espectively) were calculated using competing risk
nalysis [25].
ESULTS
atient Characteristics
Between April 1988 and June 1993, 103 patients
ith previously untreated, advanced stage FL were
egistered on 2 consecutive protocols of induction
hemotherapy followed by ABMT. The characteris-
ics of these patients have been previously described
18,20] and are summarized in Table 1. Follicular
ymphoma International Prognostic Index (FLIPI)
cores have been retrospectively assigned for the ma-
ority of patients prior to therapy, with 58% having
ntermediate FLIPI scores. All patients were under 60
ears of age, and because of the retrospective nature of
he data collection, 21% of patients had missing data
hat if known may have upstaged their FLIPI risk
roup. There were no statistically signiﬁcant differ- cnces between the patients who received SD-CHOP
r HD-CHOP [20].
Following SD-CHOP 77 of 83 patients (93%)
chieved a minimal disease state and went on to ABMT.
hree patients did not attain a protocol eligible partial
emission (PR), 2 patients were diagnosed with second
umors (melanoma and seminoma), and 1 patient de-
lined further therapy. Following 4 cycles of HD-
HOP, 19 of 20 patients were in a minimal disease state,
hereas 1 patient progressed with a high grade lym-
homa within 1 month of induction therapy. The CR
ates to SD-CHOP and HD-CHOP were 36% and
1%, respectively.
linical Outcomes
At a median follow-up of 12 years, 61% (95% CI
9.5-70.1) of patients are alive (Figure 1A), and 43%
95% CI 32.3-52.7) of patients remain in CCR (Fig-
re 1B). The overall mortality is 41%, with a median
FS of 7.3 years (95% CI 4.3-NA), and median OS of
5.8 years (95% CI 12.1-NA). Forty-six percent (N 
4) of patients have relapsed with FL, with 25% (N 
4) dying of disease, 5% (N  5) dying of other
auses, and 16% (N  15) alive following relapse
Table 2). The median time to relapse in patients who
ave relapsed was 2.3 years; only 6 relapses have oc-
able 1. Patient Characteristics
otal Registered 103
nduction
Standard-dose CHOP 83
High-dose CHOP 20
eached minimal disease, underwent
ABMT 96 (93%)
CR 35%
ge (range) 42 (19-57)
tage
II 4 (4%)
III 17 (18%)
IV 75 (78%)
DH
High 11 (11%)
Normal 64 (67%)
Missing 21 (22%)
odal sites
1-4 24 (25%)
5-8 70 (73%)
Missing 2 (2%)
LIPI
Low (0-1) 24 (25%)
Intermediate (2) 56 (58%)
High (3-5) 16 (17%)
Missing values* 20 (21%)
LIPI indicates Follicular Lymphoma International Prognostic
Index; LDH, lactate dehydrogenase; CR, complete remission;
ABMT, autologous bone marrow transplantation.
Twenty-one percent of patients had missing values assumed to be
low risk in the classiﬁcation above, which may therefore repre-
sent an underestimate of actual FLIPI score.urred at more than 6 years posttransplant. The cu-
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J. R. Brown et al.1060ulative incidence of relapse, with death in remission
competing risk, is 37% at 5 years, and 47% at 10 and
5 years (Figure 2). The median survival following
elapse is 6.1 years (95% CI 4.1-9.0). Ten patients
ave died in remission, 5 from MDS/AML, 2 early in
ospital because of diffuse alveolar hemorrhage
DAH), 1 because of suicide, and 2 of unknown causes.
he late deaths on the OS curve in Figure 1A are
igure 1. A, OS: at a median follow-up of 12 years, 61% (95% CI
ollow-up of 12 years, 43% (95% CI 32.3-52.7%) of patients remaeaths in remission, primarily resulting from MDS. bTwenty-eight percent of patients (N  27) have
eveloped a second malignancy, at a median of 8.3
ears following ABMT. These malignancies include:
0 cases of MDS/AML, 2 non-MDS hematologic ma-
ignancies, 9 solid tumors, and 10 nonmelanoma skin
ancers (Table 2). The cumulative incidence of second
alignancy, with death without second malignancy a
ompeting risk, is 16% at 10 years and is estimated to
0.1) of patients are alive. B, Progression-free survival: at a median
ngoing complete remission.49.5-7e 38% at 15 years (Figure 3). 9.4% (N  9) of
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Long-Term Results of ABMT for Follicular NHL in First Remission 1061atients have died of secondary malignancy (8 MDS/
ML, 1 metastatic breast cancer).
redictors of PFS and OS
Patient characteristics were investigated for their
bility to predict PFS or OS in univariate log-rank
nalysis. No effect of age at ABMT, stage at diagnosis,
ex, hemoglobin, lactate dehydrogenase (LDH), num-
er of nodal sites, induction therapy (SD-CHOP ver-
us HD-CHOP) or involved ﬁeld radiation therapy
as observed. No effect of FLIPI score was observed
n PFS or OS (data not shown), including when the
ubgroup of patients with missing data is analyzed
eparately. Achieving a CR after induction chemo-
herapy was of borderline signiﬁcance in predicting
able 2. Clinical Outcomes
otal subjects undergoing ABMT 96
ontinuous complete remission 42 (median F/U 12 years)
elapse (alive) 44 (15)
eaths in remission 10 (10%)
DAH 2
MDS/AML 5
Other 3 (1 suicide, 2 unknown)
econdary malignancies
(N  27 patients)
MDS/AML 10
Non-MDS heme 2
Solid 9
Breast (3); prostate (1);
rectal (1); melanoma (1);
renal cell (1); bladder (1);
anal in situ (1)
Nonmelanoma skin 10
BMT indicates autologous bone marrow transplantation; MDS,
myelodysplastic syndromes; AML, acute myelogenous leukemia;
DAH, diffuse alveolar hemorrhage.
igure 2. Cumulative incidence of relapse. The cumulative inci-
ence of relapse, with death in remission taken as a competing risk,aas 37% at 5 years and 47% at 10 and 15 years.FS (P  .05, log-rank test) but was not signiﬁcant
or OS.
Residual BM disease prior to harvest was found to
e a signiﬁcant predictor of PFS in univariate analysis,
ith subjects with no detectable tumor cells having a
2 year PFS of 50% (95% CI 34.8-63.5), whereas
hose with 5% BM involvement had PFS of 38.9%
95% CI 23.3-54.2) and those with 5%-20% BM
nvolvement, 12.5% (95% CI 0.7-42) (P  .005 log-
ank test; data not shown). No effect was observed on
S, however (data not shown, P  .21 log-rank test).
hen analyzed in a 2-group model (BM involved or
ninvolved), the results for PFS and OS are similar
data not shown).
The effect of BM purging was also analyzed in 70
atients with known detectable bcl-2/IgH transloca-
ions prior to therapy, who had postpurging BM sam-
les analyzed by PCR. Among the 30 patients whose
M infusion was PCR negative, 7 have relapsed.
mong the 40 patients whose BM infusion was PCR
ositive, 25 have relapsed. The median time to relapse
as 4.1 years in the PCR positive group, and has not
een reached in the PCR negative group, 25% of
hom have relapsed at 7.6 years (P  .0005, log-rank
est). PCR status was a signiﬁcant predictor of 12-year
FS, at 66.7% (95% CI 46.9-80.5) for the PCR neg-
tive group compared to 26.3% (95% CI 13.6-40.9)
or the PCR positive group (P  .001 log rank test;
igure 4). No statistically signiﬁcant effect was ob-
erved on OS, which was 76.7% (95% CI 57.2-88.1)
or the PCR negative group and 50.7% (95% CI
3.8-65.3) for the PCR positive group (P  .08 log
ank test).
We investigated the interaction between detect-
igure 3. Cumulative incidence of second malignancy. The cumu-
ative incidence of second malignancy, with death without second
alignancy taken as a competing risk, was 16% at 10 years and 38%
t 15 years.ble disease in the BM and the likelihood of achieving
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J. R. Brown et al.1062CR negativity after purging. Of evaluable patients
ithout histologically detectable BM disease, 21 of 35
ere PCR positive (60%). Of those with 5% BM
nvolvement, 14 of 29 were PCR positive (48%). Only
patients with 5%-20% BM involvement were evalu-
ble and 5 of 6 were PCR positive (83%; P .99 Exact
ruskal-Wallis test).
A multivariate Cox proportional hazards regres-
ion analysis was performed to evaluate the impact of
retransplant factors on PFS and OS. Variables that
ere investigated include age, sex, stage, LDH, he-
oglobin, FLIPI, number of nodal sites, type of in-
uction therapy, CR or PR after induction, presence
r absence of residual BM disease, and PCR status
fter purging. The only signiﬁcant predictors of PFS
ere presence of residual BM disease (HR 2.27 [95%
I 1.3-3.9], P  .004), and detectable disease by PCR
HR 4.18 [95% CI 1.99-8.8], P  .0002) (Table 3).
hose patients without PCR data were included in the
ultivariate model, and had an intermediate hazard
atio (HR 2.39 [95% CI 1.06-5.4], P  .04). No
igure 4. PCR detectable disease after purging predicts PFS. 12 y
ostpurging bone marrow was negative by PCR, compared to 26.3
og-rank test). No effect was observed on OS (76.7% for PCR neg
able 3. Predictors of PFS and OS
PFS: Hazard Ratio
esidual bone marrow disease 2.27 (1.3-3.9)
CR detectable disease 4.18 (1.99-8.8)
FS indicates progression-free survival; OS, overall survival.
his Cox proportional hazards model includes all 96 patients, with th
The missing category includes 19 patients whose postpurging PC
not detected by PCR.ariables were signiﬁcant predictors of OS in multi-
ariate Cox proportional hazards regression analysis.
ISCUSSION
Since the initiation of the studies reported here,
ew data have accumulated on the role of ASCT in
he treatment of follicular NHL, including data from
andomized trials that have failed to demonstrate OS
eneﬁt. The signiﬁcant incidence of long-term treat-
ent-related toxicity, particularly MDS/AML, has
lso become clear in numerous reports [1-14]. The
ole of ASCT in the treatment of FL has therefore
emained controversial. The very long-term follow-up
f this study does suggest that a signiﬁcant subset of
L patients treated with ASCT for consolidation of
rst remission can experience prolonged disease-free
urvival (DFS). Given the low frequency of late re-
apses, these data do raise the question of cure with
his modality.
was 66.7% (95% CI 46.9-80.5; n  30) for those patients whose
CI 13.6-40.9%; n  40) for those with positive PCR (P  .001
nd 50.7% for PCR positive, P  .08 log-rank test).
P OS: Hazard Ratio P
<.004 1.67 (0.87-3.2) .12
.0002 2.08 (0.9-4.6) .069
egories for postpurging PCR status: positive, negative, and missing.
not done, and 7 patients in whom a pretreatment translocation wasear PFS
% (95%ree cat
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Long-Term Results of ABMT for Follicular NHL in First Remission 1063However, given the negative randomized trials,
ate of second malignancies and availability of novel
tandard therapies that include rituximab, ASCT can-
ot be considered an appropriate standard therapy for
L in ﬁrst remission. If ASCT is to be used routinely
n patients with follicular lymphoma, patient selection
ill be critical. Since this study was designed, the
LIPI has been proposed to better standardize patient
isk and predict prognosis [26]. Although the patients
nrolled on this study were clinically perceived to be
igh risk, most are intermediate risk using the FLIPI
core, which is likely in part because of missing data
nd in part because of their young age. Direct com-
arison to FLIPI results is difﬁcult, but our observed
S of 61% at 12 years appears favorable for patients
nder 60 with intermediate FLIPI scores [26], the
losest comparison group. Furthermore, ASCT as
sed in this study appears to overcome the adverse
ffects of intermediate to high FLIPI, a ﬁnding similar
o that of the randomized trials of ASCT in FL in ﬁrst
emission [11,16,17]. These results also correlate well
ith 1 report that maintenance rituximab after induc-
ion may overcome the adverse prognosis of high
LIPI [27]. Taken together these data may suggest
hat consolidation or maintenance therapy in remis-
ion, including ASCT, may counteract the adverse
mpact of a higher risk FLIPI score. Ultimately,
mproved risk stratiﬁcation is needed, and will likely
e based on molecular features that are emerging
rom gene expression microarray studies [28].
In this study, the only disease- or ABMT-related
actors that predicted 12-year PFS were BM involve-
ent at harvest and PCR-detectable disease in the
urged BM product. These factors remain predictive
t this very long follow-up. Patients with unmistakable
istologic BM involvement were at high risk of early
elapse but were too few in number to assess the
ikelihood of achieving PCR negativity after purging.
atients with BM 5% involved histologically were
venly split with respect to PCR status, likely reﬂect-
ng 2 groups of patients: some with true disease in-
olvement who responded to purging, and others in
hom the 5% lymphoid aggregates may not have
epresented actual disease. These possibilities may ex-
lain why both BM involvement and PCR status re-
ain signiﬁcant in the multivariate model. Those pa-
ients who were PCR positive had a very high relapse
ate, possibly resulting from a direct effect of tumor
ontamination of the autograft, but alternatively PCR
ositivity may be a surrogate marker of aggressive
reatment resistant disease. Conversely, 28% of pa-
ients with PCR positive BM products remain pro-
ression-free, with a suggestion of a plateau on the
urvival curve. This ﬁnding may represent residual
NA contamination without viable cells in the purged
roduct, immunologic control of residual disease, or
ood fortune. WAssessing the true beneﬁt of ASCT has been com-
licated by the high incidence of second malignancies
fter ASCT. Deaths in remission primarily from sec-
nd malignancy may explain our inability to identify
actors predictive of OS in this study. The rate of
ong-term secondary malignancies in this ABMT pop-
lation treated in ﬁrst remission is comparable to our
reviously reported rates in the ABMT population
reated in second or greater remission [4,8], suggest-
ng that earlier use of ASCT does not reduce the
ncidence of second malignancy. In the GOELAMS
andomized trial [16] using a TBI-containing regi-
en, a higher event-free survival (EFS) for the ASCT
rm was offset in OS by excess second malignancies.
t the DFCI, second malignancies have declined since
hemotherapy-based conditioning replaced the cyclo-
hosphamide-TBI conditioning regimen used in these
tudies [4].
Ultimately the role of ASCT in the current
reatment of follicular NHL remains to be deﬁned,
articularly given the advent of nonmyeloablative
llogeneic stem cell transplantation [29-31], as well
s the range of novel antibody-based therapies, ra-
ioimmunotherapy, and small molecule targeted in-
ibitors increasingly available for the treatment of
his disease. Since the initiation of these studies,
he addition of rituximab to chemotherapy has
igniﬁcantly improved PFS and OS in FL, with
dditional beneﬁt likely from maintenance therapy
32-34]. Nonetheless, rituximab-containing thera-
ies explored to date are not likely to be curative,
nd may therefore need to be considered in combi-
ation, perhaps with ASCT. The GITMO group
ecently reported a 30% improvement in 3-year EFS for
pfront rituxan-containing high-dose therapy in com-
arison to R-CHOP, raising the possibility that
SCT outcomes may also be improved by these
ovel therapeutic approaches [35]. The similarity in
BMT outcomes reported here in DFCI patients
reated in ﬁrst remission, and our recently reported
utcomes of patients treated in second remission at
FCI and St. Bartholomew’s Hospital in London
36], suggest that FL patients treated with ASCT
hether in ﬁrst or slightly later remission may
chieve similar beneﬁts with similar risk of second
alignancy. Given the ﬁndings of the randomized
UP trial suggesting beneﬁt of ASCT in second
emission, this time point may be the most appro-
riate for further investigation of the role of ASCT
n FL, likely in combination with rituximab.
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